Antisense Oligonucleotides Targeting SARS-CoV-2

Anders Naar (Opfinder), Sakari Kauppinen (Opfinder), Chi Zhu (Opfinder), Kasper Karstensen (Opfinder)

Publikation: Patent

Abstract

COVID-19 is treated with antisense oligonucleotides (ASOs) targeting SARS-CoV-2 viral RNAs or human ACE2 RNA.

@misc{033d30b4569f4d62b427c130b2924bb4,

title = "Antisense Oligonucleotides Targeting SARS-CoV-2",

abstract = "COVID-19 is treated with antisense oligonucleotides (ASOs) targeting SARS-CoV-2 viral RNAs or human ACE2 RNA.",

author = "Anders Naar and Sakari Kauppinen and Chi Zhu and Kasper Karstensen",

year = "2022",

month = feb,

day = "10",

language = "English",

type = "Patent",

note = "C12N 15/ 86 A I",

}

TY - PAT

T1 - Antisense Oligonucleotides Targeting SARS-CoV-2

AU - Naar, Anders

AU - Kauppinen, Sakari

AU - Zhu, Chi

AU - Karstensen, Kasper

PY - 2022/2/10

Y1 - 2022/2/10

N2 - COVID-19 is treated with antisense oligonucleotides (ASOs) targeting SARS-CoV-2 viral RNAs or human ACE2 RNA.

AB - COVID-19 is treated with antisense oligonucleotides (ASOs) targeting SARS-CoV-2 viral RNAs or human ACE2 RNA.

M3 - Patent

ER -